Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
   

 

TTD Drug ID: DCL000056

Drug Information
NameAT-101
SynonymsIsosorbide (JP15/USP/INN); 1,4:3,6-dianhydrohexitol; Sorbid; CHEMBL1200660; Bio-0643; 50974-60-2; NCGC00160508-01; 1,4:3,6-Dianhydro-D-sorbitol; Isosorbida [INN-Spanish]; EINECS 211-492-3; Vascardin dinitrate; BRN 0080510; 652-67-5; Glucitol, 1,4:3,6-dianhydro-, D-; Oprea1_439690; Ismotic (TN); 2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol; AC1Q79SL; 42750-75-4; Isosorbide [USAN:INN:BAN:JAN]; TL8004635; 67803-92-3; STK801813; I0407; HSDB 3105; AC1L4190; Isobide; SMP1_000177; EINECS 248-906-7; AR-1B7417; NSC 40725; EINECS 211-374-1; BIDD:GT0695; Devicoran; 49871-92-3; Isosorbidum [INN-Latin]; D-Sorbitol, 1,4:3,6-dianhydro(furo[3,2-b]furan-3,6-diol, hexahydro-); 24332-71-6; MolPort-001-783-404; I14-6752; 1,4:3,6-Dianhydroglucitol; LS-71370; Isobide (TN); NSC40725; D00347; UNII-WXR179L51S; D-Glucitol, 1,4:3,6-dianhydro-; D-Sorbitol, {1,4:3,6-dianhydro(furo[3,2-b]furan-3,6-diol,} hexahydro-); LS-89261; Hydronol; Sorbitol, 1,4:3,6-dianhydro-; Isosorbidum; 1,4:3,6-Dianhydromannitol; 151380-60-8; A912284D-27E1-4FB0-91B8-86C8AB905297; 5-19-03-00201 (Beilstein Handbook Reference); 641-74-7; NSC270938; 152881-21-5; Hydronol (VAN); Isomannide; D-1,4:3,6-Dianhydroglucitol; isosorbide; 1,4:3,6-Dianhydro-D-glucitol; (3S,3aR,6R,6aR)-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan-3,6-diol; Ismotic; (+)-D-Isosorbide; AT-101; CID99937; AC1L1ZXO; Dianhydrosorbitol; D-Mannitol, 1,4:3,6-dianhydro-; KST-1B7297; CID12597; AT 101; ZINC18284778; Isosorbida; D-Glucitol, 1,4:3,6-dianhydro-; 28218-68-0; MolPort-000-812-960; Mannitol, 1,4:3,6-dianhydro-; NSC231906; Dianhydro-D-glucitol; 1,4:3,6-Dianhydrosorbitol; 1,4-Dianhydrosorbitol
CompanyAscenta Therape.
IndicationLymphoid Leukemia, Non-Hodgkin's Lymphoma, Prostate Cancer
[ICD9: 140-229, 185, 200, 202, 202.8, 208.9   ICD10: C00-C96, C61, C81-C96, C82-C85, C91-C95]
Phase II    
Structure

Click to save drug structure in 3D MOL format

Click to save drug structure in 2D MOL format
InChI1S/C6H10O4/c7-3-1-9-6-4(8)2-10-5(3)6/h3-8H,1-2H2/t3-,4+,5-,6-/m1/
s1
InChIKeyKLDXJTOLSGUMSJ-JGWLITMVSA-N
Canonical SMILESC1C(C2C(O1)C(CO2)O)O    
Isomeric SMILESC1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)O)O
Therapeutic ClassAntineoplastic Agents
CAS NumberCAS 652-67-5
PubChem Compound IDCID 12597.
PubChem Substance IDSID 155927.
SuperDrug ATC IDC01DA08
ClinicalTrials.govNCT00440388;
TargetAntiapoptotic protein BCL-XLInhibitor[1]
Antiapoptotic protein BCL-XLMultitarget[1]
Apoptosis regulator Bcl-2Inhibitor[1]
Apoptosis regulator Bcl-2Multitarget[1]
Mcl-1Inhibitor[2]
Mcl-1Multitarget[2]
Ref 1Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther. 2009 Aug 8;8(16). [Epub ahead of print] To Reference
Ref 2An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res. 2009 May 1;15(9):3172-6. Epub 2009 Apr 14. To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

   
 
 
Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links

 

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543